Can Abdominal CT Detect Pancreatic Cancer?

Yes, abdominal computed tomography (CT) is a cornerstone imaging modality for the detection, characterization, and staging of pancreatic cancer. With intravenous contrast administration—particularly using multiphase protocols that include pancreatic parenchymal and portal venous phases—CT achieves high sensitivity and specificity for identifying primary pancreatic malignancies, including ductal adenocarcinoma, the most common histologic subtype.

Modern multidetector CT scanners provide subcentimeter spatial resolution, enabling visualization of subtle morphologic changes such as focal pancreatic enlargement, hypodense masses, ductal dilatation (e.g., double-duct sign), vascular encasement, peripancreatic fat stranding, and regional lymphadenopathy. Contrast-enhanced CT also plays a critical role in assessing resectability by evaluating tumor abutment or invasion of key vessels—including the superior mesenteric artery, celiac axis, and portal vein—as well as detecting distant metastases, most commonly in the liver and peritoneum.

While CT is highly effective as a first-line diagnostic tool, its performance may be limited in detecting very small lesions (<1 cm), differentiating benign from malignant cystic neoplasms, or evaluating indeterminate findings. In such cases, complementary modalities—including endoscopic ultrasound (EUS) with fine-needle aspiration, magnetic resonance imaging (MRI) with MR cholangiopancreatography (MRCP), or positron emission tomography–CT (PET-CT)—may be warranted for further evaluation or tissue confirmation.

Clinically, abdominal CT is recommended in patients presenting with unexplained weight loss, painless jaundice, new-onset diabetes mellitus after age 50, or persistent upper abdominal pain—especially when risk factors such as smoking, chronic pancreatitis, or familial pancreatic cancer syndromes are present.